Clinical Trial Update: An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneously administered ustekinumab for moderate to severe chronic plaque psoriasis in pediatric patients aged 6 to <12 years; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-28